Biomed-Lublin to build new factory

…the products Biomed will be focusing on. The rights to Lackid were sold to Polpharma a few weeks ago, but the company will continue to produce the drug on a contract basis. Biomed-Lublin plans to announce a new strategy in March 2018, Mr Pirog also revealed.  

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.